Research and Markets: How Feasible is Blockbuster Drug Development as a Foundation of Major Pharma Growth?

Research and Markets (researchandmarkets.com/reports/c9320) has announced the addition of Future Growth Strategies: Drivers of sustainable development within the biotech, specialty and major pharma sectors to their offering.

(PRWEB) November 17, 2004 -- Research and Markets (http://www.researchandmarkets.com/reports/c9320) has announced the addition of Future Growth Strategies: Drivers of sustainable development within the biotech, specialty and major pharma sectors to their offering.

Where are the pharma and biotech sectors heading for the remainder of 2004 and beyond...? This management report provides the timely analysis senior executives need to maximize business opportunities in 2004. This report assesses favored growth strategies for pharma and biotechs and offers productive solutions to assure long-term success. This report examines the feasibility of blockbuster drug development as a foundation of major pharma growth and proposes alternatives to expansion through M&A, expounding the benefits of in-licensing and then networked growth. It also focuses on the group of small ethical, generics, drug delivery and certain biotech firms that together constitute the specialty pharma sector. Fundamentally, this report provides the analysis required to take advantage of new market opportunities and prepare counter strategies for threats presented by new entrants.

Contents Include:
-Major pharma
Summary
Introduction: major pharma health check
Blockbuster growth model
Demand for blockbuster drugs
Investors emphasis on revenues
Optimizing returns on pharmaceutical R&D
Innovation is more sustainable than patent defense
Current blockbuster market
Reliance on blockbuster sales
Is blockbuster growth sustainable?
Growth through M&A
Drivers of pharmaceutical M&A
Focus on productivity improvements
The productivity crisis in R&D
The productivity crisis in sales
Is consolidation the answer?
Downsizing to improve efficiency -- short-term gains
Revenues are directly proportional to investment in sales -- no scale economies
Pipeline productivity is directly proportional to R&D investment -- no scale economies
Implications for major pharma
Outlook for the major pharma sector
From blockbuster to 'multi-buster -- opportunities arising from pharmacogenomics
Treatment by genotype
Improvements in diagnosis
Maximizing revenues in the post-genomics era
Focus on core competencies -- benefits of networked growth
Short-term tactics -- becoming the licensing partner of choice
Longer term strategy -- moving from licensing to networking

Chapter 2 Specialty pharma
Summary
Introduction: specialty pharma health check
Growth-by-acquisition business model
Search strategies
Acquisitions
Single product acquisitions
Franchise acquisitions
Corporate acquisitions
Focused sales and marketing activities
Limitations of the growth-by-acquisition model
High cash burn
Over-reliance on individual product acquisitions
Lack of appropriate acquisition targets
Best acquisition targets too expensive
Outlook for specialty pharmas
Growth drivers to 2007
Continued top tier consolidation liberates products for specialty pharmas
Large pharmas ignore therapeutic markets with lower revenue potential
Revenue window of opportunity for specialty pharmas
Patent expiries fuel generic and drug delivery company growth
Biotechs move downstream
Japanese market opens up to specialty pharmas
Barriers to short-term growth
Growth drivers, 2007-12
Genomics and related technologies yield more drug targets
Pharmacogenomics micro-segments disease markets
Introduction of biogeneric drugs
Major pharmas divest entire therapeutic franchises
Barriers to longer term growth
Winning growth strategies
Improved search strategies and better structured agreements
Targeting the right therapy areas
Creating partnership networks
Acquire or co-promote?
Moving upstream to reduce reliance on acquisitions

Chapter 3 Biotech
Summary
Introduction: biotech health check
The evolving biotech market
Changing competitive landscape
Intra-biotech competition
Biotech-pharma competition
Changing balance of power between biotech and pharma
Desire for independence
Stratification of biotech sector
Growth strategies
Biotech growth influences
Cost containment
Income
Perception
Product potential
Adoption of growth strategies by biotechs at different stages of development
Integrated biotechs
Developing biotechs
Co-development companies
Platform technology companies
Outlook for the biotech sector
Integrated biotechs will consolidate to improve productivity
Developing and co-development companies will work together to avoid restrictive agreements with pharmas
Development stage companies will partner rather than go-it-alone to market
Platform technology companies will expand their services to protect against mimicry

For more information visit http://www.researchandmarkets.com/reports/c9320

Laura Wood
Senior Manager
Research and Markets
press@researchandmarkets.com
Fax: +353 1 4100 980

###